Effect of a spacer on total systemic and lung bioavailability in healthy volunteers and in vitro performance of the Symbicort® (budesonide/formoterol) pressurized metered dose inhaler

Abstract

The clinical study demonstrated that in subjects with poor inhalation technique the use of the AeroChamber Plus^® Flow-Vu^® spacer increased the bioavailability of Symbicort^® pMDI to a level observed in subjects with good inhalation technique without a spacer. The findings from the in vitro study support the fine particle dose characteristics of Symbicort^® pMDI with the AeroChamber Plus^® Flow-Vu^® spacer.